Gilead Sciences has made another foray into the natural killer (NK) cell category, paying $300 million upfront to access Dragonfly Therapeutics' TriNKET platform to find therapies for cancer and ...

Bristol-Myers Squibb has signed an agreement worth $475 million to develop a new form of cancer immunotherapy drug with US biotech Dragonfly Therapeutics. BMS is best known as an early pioneer of ...

James Chen, CMT is an expert trader, investment adviser, and global market strategist. Somer G. Anderson is CPA, doctor of accounting, and an accounting and finance professor who has been working in ...

A central pattern generator (CPG) is a neuronal network in which interconnected excitatory and inhibitory neurons produce an oscillating, rhythmic output in the absence of sensory feedback. CPGs play ...

Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.